1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX dividend stock Sonic Healthcare Ltd (ASX: SHL) has dropped 43% since the COVID-19 peak of December 2021. This business provides pathology services for patients in a number of countries, including Australia, the UK, Germany, Switzerland, New Zealand and the USA.

It's understandable why the company has fallen so far, since investors typically value an ASX share based on how much profit it's making. The company played a big part in all of the COVID-19 testing that helped identify who had the illness. However, COVID-19 testing revenue has now ended as a meaningful contributor to Sonic. Accordingly, it's just organic growth that contributes to the business now.

For two reasons, I think this ASX dividend stock could be a good one to focus on.

A scientist examining test results.

Image source: Getty Images

Solid dividend

Over the past 30 years, the business has grown its dividend most years. It has increased its payout every year since 2013. That's one of the stronger dividend records on the ASX, thanks to its exposure to healthcare earnings.

The last two dividends declared came to a total dividend per share of $1.07. This is a dividend yield of 4%, with no franking credits. If it did start attaching franking credits to the dividend, this would be a larger dividend.

I think the dividend could continue climbing in the coming years because of its resilient earnings, despite global share market headwinds.

Defensive earnings

Healthcare is a very defensive sector in my opinion – people don't choose when to get sick based on what's going on with the economy, the stock market or GDP.

Sonic Healthcare isn't a high-risk biotech stock, it provides important pathology services that is used by various patients across the world.

The ASX dividend stock has made a number of acquisitions, particularly in Europe, to boost its scale. Not only does this boost the revenue, but the company can also find cost and technology synergies between the businesses.

For example, it's investing in AI to help improve patient outcomes and improve efficiencies for the business.

According to the forecast on Commsec, the Sonic Healthcare share price is valued at 25x FY25's estimated earnings. I think that's an appealing valuation.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »